AVEO Pharmaceuticals - 48 Year Dividend History | AVEO

Historical dividend payout and yield for AVEO Pharmaceuticals (AVEO) since 1971. The current TTM dividend payout for AVEO Pharmaceuticals (AVEO) as of April 23, 2019 is $0.00. The current dividend yield for AVEO Pharmaceuticals as of April 23, 2019 is 0.00%.
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.152B $0.005B
AVEO Pharmaceuticals, Inc. is a biopharmaceutical company engaged in discovering, developing and commercializing novel cancer therapeutics. Its product candidates are targeted against important mechanisms known or believed to be involved in cancer. Tivozanib, the Company's lead product candidate, is a highly potent and selective oral inhibitor of the vascular endothelial growth factor, or VEGF, receptors 1, 2 and 3. In addition to tivozanib, AVEO Pharmaceuticals has a pipeline of monoclonal antibodies derived from Human Response Platform (HRP), a novel method of building preclinical models of human cancer, which are intended to more accurately represent cancer biology in patients. AV-299 is the Company's next product candidate which is an antibody that binds to hepatocyte growth factor, or HGF, thereby blocking its function. AVEO Pharmaceuticals, Inc. is based in Cambridge, Massachusetts.
Stock Name Country Market Cap PE Ratio
Amgen (AMGN) United States $108.629B 12.24
Gilead Sciences (GILD) United States $78.878B 10.04
Bio-Techne Corp (TECH) United States $7.219B 48.64